NEW YORK, NY
Flatiron Health today announced 11 abstracts accepted for presentation at the 2018 American Society for Clinical Oncology (ASCO) Annual Meeting, which will be held June 1-5 in Chicago. The research, spanning multiple tumor types and areas of study, utilized Flatiron’s highly-curated, nationally-representative, real-world oncology datasets, the largest in the United States.
The research to be presented includes collaborations with the Abramson Cancer Center of the University of Pennsylvania, Fred Hutchinson Cancer Research Center, Genentech (a member of the Roche Group), Huntsman Cancer Institute at the University of Utah, the National Cancer Institute, Roche, the U.S. Food & Drug Administration, and Yale Cancer Center.
The presentation schedule and links to abstracts can be found below. To learn more about Flatiron Health, visit our booth #2049 during the conference or click here.
Oral Presentation
Application of a real-world endpoint to identify and characterize genetic profiles of patients (pts) with poor prognosis in advanced non-small-cell lung cancer (aNSCLC)
Presenting Author: Greg Riely (Memorial Sloan Kettering Cancer Center)
Date/Time: 6/5/2018, 10:00 – 10:12 AM
Abstract: #12006
Location: S406
Session: Tumor Biology
Poster Discussion Presentation
Cost-effectiveness of multi-gene panel sequencing (MGPS) for advanced non-small cell lung cancer (aNSCLC) patients
Presenting Author: Lotte Steuten (Fred Hutchinson Cancer Research Center)
Date/Time: 6/2/2018, 4:45 – 6:00 PM
Abstract: #6513
Poster: #339
Location: S102
Session: Health Services Research, Clinical Informatics, and Quality of Care
Poster Presentations (Location: Hall A)
Real-world (RW) characteristics, treatment (tx) patterns, and overall survival (OS) in US patients (pts) with metastatic breast cancer (mBC) and CNS metastases (CNS mets)
Presenting Author: Ashwini Shewade (Genentech, a member of the Roche Group)
Date/Time: 6/2/2018, 8:00 – 11:30 AM
Abstract: #1037
Poster: #118
Session: Breast Cancer—Metastatic
Diffusion of innovation in oncology: A case study of immuno-oncology (IO) adoption for advanced non-small lung cancer (aNSCLC) patients across practices in the US
Presenting Author: Carrie Bennette (Flatiron Health)
Date/Time: 6/2/2018, 1:15 – 4:45 PM
Abstract: #6537
Poster: #363
Session: Health Services Research, Clinical Informatics, and Quality of Care
Association of baseline body mass index (BMI) with overall survival (OS) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC) treated with nivolumab (N) and pembrolizumab (P)
Presenting Author: Jizu Zhi (U.S. Food & Drug Administration)
Date/Time: 6/2/2018, 1:15 – 4:45 PM
Abstract: #6553
Poster: #379
Session: Health Services Research, Clinical Informatics, and Quality of Care
Development of a dashboard for end-of-life care at an academic hospital
Presenting Author: Kerin Adelson (Yale Cancer Center)
Date/Time: 6/2/2018, 1:15 PM – 4:45 PM
Abstract: #6590
Poster: #415
Session: Health Services Research, Clinical Informatics, and Quality of Care
Real-world data (RWD) on tumor response (rwTR) in advanced non-small cell lung cancer (aNSCLC) patients receiving cancer immunotherapy and targeted therapies
Presenting Author: Michael W Lu (Genentech, a member of the Roche Group)
Date/Time: 6/2/2018, 1:15 – 4:45 PM
Abstract: #6578
Poster: #403
Session: Health Services Research, Clinical Informatics, and Quality of Care
Comparative effectiveness of carboplatin-pemetrexed (carbo-pem) with vs without bevacizumab (bev) in patients with advanced non-squamous (sq) non-small cell lung cancer (NSCLC)
Presenting Author: Stephen Bagley (Abramson Cancer Center of the University of Pennsylvania)
Date/Time: 6/3/18, 8:00 – 11:30 AM
Abstract: #9073
Poster: #396
Session: Lung Cancer—Non-Small Cell Metastatic
Age-related real-world outcomes for patients (pts) with metastatic colorectal cancer (mCRC)
Presenting Author: Rebecca Miksad (Flatiron Health)
Date/Time: 6/3/2018, 8:00 – 11:30 AM
Abstract: #3613
Poster: #106
Session: Gastrointestinal (Colorectal) Cancer
Immune checkpoint inhibitor (ICI) treatment in advanced melanoma (aMel) patients (pts) with hepatic or renal dysfunction (dysf): Real-world patient characteristics and outcomes
Presenting Author: Susan Spillane (National Cancer Institute)
Date/Time: 6/4/2018, 1:15 – 4:45 PM
Abstract: #9569
Poster: #396
Session: Melanoma/Skin Cancers
Risk stratification using patient-reported outcomes (PROs) in patients (pts) with advanced cancer
Presenting Author: Shiven Patel (Huntsman Cancer Institute at the University of Utah)
Date/Time: 6/4/2018, 1:15 – 4:45 PM
Abstract: #10101
Poster: #89
Session: Patient and Survivor Care
About Flatiron Health
Flatiron Health is a healthtech company expanding the possibilities for point of care solutions in oncology and using data for good to power smarter care for every person with cancer. Through machine learning and AI, real-world evidence, and breakthroughs in clinical trials, we continue to transform patients’ real-life experiences into knowledge and create a more modern, connected oncology ecosystem. Flatiron Health is an independent affiliate of the Roche Group.
